Speculative M&A Transaction Analysis, page-807

Big biotech deals don't happen overnight, they often take years and involve a lot of tyre-kicking and DD (big and fast don't often go together). Extracting maximum value from Bisantrene will require having the right data (Phase 2) and a bidding war. This is going to take time, but we can do regional deals along the way.

Nobody other than me has to stay for the whole RAC journey. As long as we make significant progress and tick-off the various activities that we need to do for a deal then shareholders can expect the SP to rise allowing anyone to get off at any stage that suits their particular needs. We have seen this with CU6 over the last 12 months where the SP has risen massively despite CU6 not making any deal with any pharma company. They have generated good data, had some luck, and are now a $2 billion company. The only complaining I hear about CU6 shareholders is why they didn't get in sooner.